扶正解毒方联合信迪利单抗+Nab-PP方案治疗中晚期非小细胞肺癌患者临床观察  

Clinical Observation of Fuzheng Jiedu Prescription Combined with Sindilizumab+Nab-PP Regimen in Treatment of Patients with Advanced Non-small Cell Lung Cancer

作　　者：凌震 杨静 杨礼畅 LING Zhen;YANG Jing;YANG Lichang(Anhui University of Chinese Medicine,Anhui Hefei 230012,China;Xuzhou Traditional Chinese Medicine Hospital,Jiangsu Xuzhou 221000,China;Nanjing University of Traditional Chinese Medicine,Jiangsu Nanjing 210023,China)

机构地区：[1]安徽中医药大学研究生院,安徽合肥230012 [2]江苏省徐州市中医院,江苏徐州221000 [3]南京中医药大学研究生院,江苏南京210023

出　　处：《中医药临床杂志》2024年第5期944-948,共5页Clinical Journal of Traditional Chinese Medicine

基　　金：徐州市科技局重点研发项目:(KC21263)。

摘　　要：目的:观察扶正解毒方联合新替利单抗+Nab-PP方案治疗晚期癌症的疗效和安全性。方法:选择2022年1月—2023年5月徐州市中医医院收治的40例晚期癌症患者。采用随机分组法分为对照组和治疗组,每组20例。对照组单用信迪利单抗+Nab-PP方案治疗,治疗组用信迪利单抗+Nab PP方案联合扶正解毒治疗。观察两组患者4个疗程后的疾病控制率、治疗前后肿瘤标志物指标、中医证候积分变化及不良反应。结果:治疗组的疾病控制率为80.0%,对照组为70.0%,差异无统计学意义(P>0.05);治疗组血清细胞角蛋白19片段、糖类抗原125和癌胚抗原水平较治疗前下降,具有统计学意义(P<0.05),与对照组比较,下降更为显著,具有统计学显著性(P<0.05),糖类抗原125的下降无统计学意义(P>0.05)。中医证候积分比较,治疗组分数低于对照组,差异有统计学意义(P<0.05)。在呕吐、腹泻、食欲减退等方面的不良反应,差异有统计学意义(P<0.05),但在皮疹、甲状腺功能障碍、骨髓抑制等方面优于对照组,但无统计学意义(P>0.05)。结论:扶正解毒方能有效改善晚期癌症非小细胞肺癌患者的生活质量,提高信迪利单抗+Nab-PP方案的疗效,减少不良反应。Objective:To observe the efficacy and safety of Fuzheng Jiedu prescription combined with neotilizumab+Nab-PP regimen in the treatment of advanced cancer.Methods:40 patients with advanced cancer admitted to Xuzhou Traditional Chinese Medicine Hospital from January 2022 to May 2023 were selected.The patients were divided into control group and treatment group by random grouping method,with 20 cases in each group.The control group was treated with the sintilimab+Nab-PP regimen alone,and the treatment group was treated with the sintilimab+Nab PP regimen combined with Fuzhengjiedu.The disease control rate,tumor marker indicators before and after treatment,changes in TCM syndrome scores and adverse reactions of the two groups of patients after 4 courses of treatment were observed.Results:The disease control rate in the treatment group was 80.0%,and that in the control group was 70.0%.The difference was not statistically significant(P>0.05).The levels of CYFRA21-1,CA125 and CEA in the treatment group were lower than before treatment,which was statistically significant(P<0.05),compared with the control group,the decrease was more significant and statistically significant(P<0.05).The decrease in CA125 was not statistically significant(P>0.05).Comparing the TCM syndrome scores,the scores of the treatment group were lower than those of the control group,and the difference was statistically significant(P<0.05).There were statistically significant differences in adverse reactions such as vomiting,diarrhea,and loss of appetite(P<0.05).However,in terms of rash,thyroid dysfunction,and bone marrow suppression,it was better than the control group in terms of rash,thyroid dysfunction,and bone marrow suppression,but there was no statistical significance(P>0.05).Conclusion:Fuzheng Jiedu Recipe can effectively improve the quality of life of patients with advanced non-small cell lung cancer,improve the efficacy of sintilimab+Nab-PP regimen,and reduce adverse reactions.

关 键 词：非小细胞肺癌 扶正解毒汤 信迪利单抗 Nab-PP方案 

分 类 号：R734.2[医药卫生—肿瘤]